ImmuCell logo

ImmuCellNASDAQ: ICCC

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 May 1987

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$32.08 M
-61%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector
-51%vs. 3y high
43%vs. sector
-66%vs. 3y high
29%vs. sector

Price

regular market | Wed, 20 Nov 2024 21:00:00 GMT
$3.60$0.00(0.00%)

Dividend

No data over the past 3 years
$6.01 M-$701.70 K

Analysts recommendations

Institutional Ownership

ICCC Latest News

ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges
zacks.com19 November 2024 Sentiment: POSITIVE

ICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product.

ImmuCell Corporation (ICCC) Q3 2024 Earnings Call Transcript
seekingalpha.com14 November 2024 Sentiment: NEUTRAL

ImmuCell Corporation (NASDAQ:ICCC ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Joe Diaz - Lytham Partners Michael Brigham - President and CEO Conference Call Participants George Melas - MKH Management Operator Good morning and welcome to ImmuCell Corporation Reports Third Quarter September 30, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
globenewswire.com08 October 2024 Sentiment: POSITIVE

PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024
globenewswire.com13 August 2024 Sentiment: POSITIVE

PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
globenewswire.com09 July 2024 Sentiment: POSITIVE

PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2024, which ended June 30, 2024.

ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®
globenewswire.com05 June 2024 Sentiment: POSITIVE

PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain ®.

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
globenewswire.com04 June 2024 Sentiment: POSITIVE

PORTLAND, Maine, June 04, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 13, 2024, at 9:30 AM ET, as previously disclosed in its Proxy Statement filed with the Securities and Exchange Commission (“SEC”) on April 26, 2024.

ImmuCell Corporation (ICCC) Q1 2024 Earnings Call Transcript
Seeking Alpha15 May 2024 Sentiment: POSITIVE

ImmuCell Corporation (NASDAQ:ICCC) will be hosting a conference call to discuss their Q1 2024 financial results on May 15, 2024 at 9:00 AM ET. Company representatives include Joe Diaz and Michael Brigham. Participants in the call include Michael Potter, Maynard Fernandez, and Sean Kirkwood. The operator will begin the call with a welcome message.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
GlobeNewsWire07 November 2023 Sentiment: NEGATIVE

Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
GlobeNewsWire07 August 2023 Sentiment: POSITIVE

PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023. The Company has scheduled a conference call the next morning, Friday, August 11, 2023, at 9:00 AM ET to review its second quarter financial results.

What type of business is ImmuCell?

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

What sector is ImmuCell in?

ImmuCell is in the Healthcare sector

What industry is ImmuCell in?

ImmuCell is in the Biotechnology industry

What country is ImmuCell from?

ImmuCell is headquartered in United States

When did ImmuCell go public?

ImmuCell initial public offering (IPO) was on 05 May 1987

What is ImmuCell website?

https://immucell.com

Is ImmuCell in the S&P 500?

No, ImmuCell is not included in the S&P 500 index

Is ImmuCell in the NASDAQ 100?

No, ImmuCell is not included in the NASDAQ 100 index

Is ImmuCell in the Dow Jones?

No, ImmuCell is not included in the Dow Jones index

When was ImmuCell the previous earnings report?

No data

When does ImmuCell earnings report?

The next expected earnings date for ImmuCell is 28 February 2025